EQ504 / Equillium - LARVOL DELTA

Phase 1 proof-of-mechanism study of EQ504 on track to initiate in mid-2026, with data expected approximately six months thereafter. (Equillium Bio Press Release) - "Continuing to advance EQ504, a potent and selective AhR modulator with potential for targeted local delivery in gastrointestinal (GI) diseases, including UC, as well as inhaled formulations for inflammatory lung diseases. Equillium recently presented two EQ504 abstracts at IMMUNOLOGY 2026, the annual meeting of the American Association of Immunologists in April 2026. Preclinical findings demonstrate that EQ504 promotes immune tolerance through induction of IL-10 and IL-22, supports anti-inflammatory macrophage polarization, and enhances epithelial repair and barrier function. Evaluating further advancement of EQ302, its oral, bi-specific inhibitor of IL-15 and IL-21 being developed for GI indications, including celiac disease."

New P1 trial • P1 data • Preclinical • Celiac Disease • Inflammatory Bowel Disease • Ulcerative Colitis

EQ504, a Potent AhR Modulator, Promotes Epithelial Repair and Barrier Restoration Compared to Clinically Validated AhR Agonists. (IMMUNOLOGY 2026) - "These findings demonstrate that EQ504 is a potent AhR agonist with superior epithelial repair and barrier-stabilizing activity compared to obefazimod. The ability of EQ504 to promote IL-22 responsiveness while reducing CLDN2 expression highlights functional differentiation among AhR-targeting therapies and supports its development as a promising treatment for inflammatory mucosal diseases."

Clinical • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis • CLDN2 • IL22 • IL2RA

EQ504: A Novel AhR Modulator That Promotes Immune Tolerance Through Il-10 and Il-22 Cytokine Release (IMMUNOLOGY 2026) - "Despite its therapeutic potential inflammatory bowel disease (IBD), clinical development of AhR modulators has been limited by the lack of potent, selective and drug-like molecules. We evaluated EQ504, a novel small-molecule AhR modulator derived from the endogenous ligand ITE and obefazimod, a clinically validated molecule in IBD. These findings identify EQ504 as a potent next generation AhR modulator with a unique immunoregulatory profile. EQ504 promotes Tr1mediated immune tolerance and anti-inflammatory macrophage polarization, mechanisms highly relevant to the treatment of IBD."

Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • FOXP3 • GZMB • IL10 • IL1B • IL22 • IL6 • TNFA

Equillium Announces Poster Presentations at IMMUNOLOGY2026, the Annual Meeting of the American Association of Immunologists (The Manila Times) - "We are excited to share these preclinical findings that support the differentiated profile of EQ504 as a potent AhR modulator, with the potential to influence both immune cell responses and barrier restoration."

Preclinical • Immunology

Equillium (NASDAQ: EQ) expands autoimmune pipeline and raises $65M in private financings (StockTitan.net) - "The company reports two sizable private placements: about $30.0 million in August 2025 plus $35.0 million in March 2026, with up to $20.0 million more contingent on milestones. Management believes this cash extends the runway into 2029, giving time to execute a Phase 1 program for EQ504 and advance EQ302 manufacturing and toxicology work...Risks remain typical for early-stage biotech: continued losses, dependence on additional capital, regulatory uncertainty, manufacturing reliance on CMOs, and potential Nasdaq listing compliance issues. Future disclosures on the planned mid‑2026 Phase 1 start for EQ504 and subsequent data readout will be key to assessing progress."

Financing • New P1 trial • Celiac Disease • Ulcerative Colitis

Equillium to Host Ulcerative Colitis KOL Event on November 5, 2025 (GlobeNewswire) - "Presenters will review preclinical data demonstrating EQ504’s differentiated mechanism of action – enhancing IL-10 and IL-22 signaling, driving regulatory T-cell function, and protecting epithelial barrier integrity – and discuss the company’s plans for a Phase 1 proof-of-mechanism study expected to initiate mid-2026."

New P1 trial • Preclinical • Ulcerative Colitis

Equillium Announces Up to $50 Million Financing to Advance EQ504, a Novel Aryl Hydrocarbon Receptor Modulator, into the Clinic (Businesswire) - "...'This funding marks a significant milestone for Equillium, enabling us to accelerate the clinical development of EQ504 into a Phase 1 proof-of-mechanism study in mid-2026, with data expected to follow approximately six months thereafter'."

Financing • New P1 trial • Ulcerative Colitis

Potent AhR Agonist EQ504 Facilitates Gut Epithelial Repair in Inflammatory Disease Models (IMMUNOLOGY 2025) - "EQ504 also induced upregulation of IL-10 expression, a key anti-inflammatory cytokine, thereby highlighting its potential as a therapeutic agent for managing intestinal inflammation and promoting mucosal recovery. These findings demonstrate the efficacy of EQ504 in promoting healing of gut epithelial cells from inflammation and damage, highlighting its potential therapeutic value for patients with inflammatory mucosal diseases.Keywords: Animals Human; Diseases Autoimmunity; Molecules Transcription Factors; Processes Inflammation; Tissues Mucosa"

Inflammation • Inflammatory Bowel Disease • IFNG • IL10 • IL1B • TNFA

EQ504: A Potent Derivative of the AhR Ligand ITE Demonstrates Efficacy in Modulating Inflammation and Promoting Healing in DSS-Colitis (IMMUNOLOGY 2025) - "EQ504 demonstrated superior potency compared to other AhR ligands, with similar efficacy to tapinarof, an FDA-approved AhR topical treatment. In an acute DSS colitis model, EQ504 (1 mg/kg) significantly alleviated clinical symptoms, including body weight loss, colon length reduction, and tissue pathology. These findings highlight the therapeutic potential of EQ504 in treating gut inflammation by modulating immune responses and enhancing tissue repair.Keywords: Animals Rodent; Diseases Autoimmunity; Molecules Transcription Factors; Processes Gene Regulation"

Clinical • Late-breaking abstract • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • AHR • IL10 • IL22

EQ504: A Novel AhR Agonist That Promotes Immune Tolerance Through Modulating T Cell Function (IMMUNOLOGY 2025) - "Conversely, during Th17 differentiation, EQ504 significantly decreased expression of IL-17A and IL-17F while increasing the expression of IL-22, which plays a pivotal role in maintaining barrier function in tissues such as the gut and skin2. EQ504 drives potent Treg stability and function, highlighting AhR modulation as a transformative strategy to rebalance Teff/Treg ratios in immunoinflammatory diseases.Keywords: Animals Human; Cells T Cells; Molecules Cytokines; Processes Cell Activation Tolerance/Suppression/Anergy"

IO biomarker • Inflammation • ENTPD1 • FOXP3 • IL10 • IL17A • IL22 • TIGIT

Equillium Announces Multiple Poster Presentations Highlighting EQ504 at the Annual Meeting of The American Association of Immunologists (Businesswire) - "Equillium, Inc...today announced that three posters were presented at IMMUNOLOGY2025, the annual meeting of The American Association of Immunologists taking place at the Hawaiʻi Convention Center in Honolulu, Hawaii, May 3 – 7; EQ504 protects against gut damage in a mouse model of ulcerative colitis;EQ504 increases Treg stability and function while suppressing pathogenic Th17 responses; EQ504 promotes healing of intestinal epithelial cells by promoting anti-inflammatory cytokines."

Preclinical • Ulcerative Colitis